AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Depreciation, amortisation & impairment added back in by Year
Depreciation, amortisation & impairment added back in EBITDA ($M) ($M)
AstraZeneca Depreciation, amortisation & impairment added back in: $5,733M in FY2025, down 14.3% from a year earlier.
Where the FY2025 figure comes from
“|| Depreciation, amortisation and impairment | 5,733 | 6,688 | (14) | (15) | 1,511 | 2,337 | (35) | (37)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F EBITDA Reconciliation Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Depreciation, amortisation & impairment added back in EBITDA ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,733 | -14.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 6,688 | +24.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 5,387 | -1.7% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 5,480 | -16.1% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 6,530 | +107.4% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 3,149 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Depreciation, amortisation & impairment added back in ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ebitda-da-impairment
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.